Posted by Michael Wonder on 06 Jun 2023
Novartis receives European approval for Cosentyx as first and only IL-17A inhibitor for hidradenitis suppurativa
1 June 2023 - European approval is based on robust Phase 3 data showing Cosentyx provided rapid symptom relief from as early as week 4, with response rates continuing to improve up to 1 year.
Novartis announced today that the European Commission has approved Cosentyx (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an inadequate response to conventional systemic HS therapy.
